Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PA31 | ISIN: US68621F1021 | Ticker-Symbol: 2PQ
Tradegate
19.11.24
19:51 Uhr
3,840 Euro
+0,060
+1,59 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ORGANOGENESIS HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
ORGANOGENESIS HOLDINGS INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,8603,92018:27
3,8603,92018:27

Aktuelle News zur ORGANOGENESIS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrOrganogenesis Holdings Inc.: Organogenesis Commends Final LCDs1
13.11.Organogenesis Holdings Inc reports results for the quarter - Earnings Summary2
13.11.Organogenesis Holdings Inc. - 8-K, Current Report1
12.11.Organogenesis secures $130 million investment1
12.11.Organogenesis announces $130M private placement offering3
12.11.Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock2
11.11.Organogenesis Holdings Inc.: Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis83CANTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
► Artikel lesen
ORGANOGENESIS Aktie jetzt für 0€ handeln
16.10.Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 20242
01.10.Organogenesis Holdings Inc.: Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers2
04.09.Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September1
09.08.Earnings call: Organogenesis exceeds Q2 revenue expectation at $130.2 million2
09.08.Organogenesis files for mixed shelf offering of up to $250M1
08.08.Organogenesis Holdings Inc.: Organogenesis Shares ReNu® Program Update2
08.08.Organogenesis Holdings Inc. - 8-K, Current Report-
20.07.Organogenesis Holdings Inc. (ORGO): Is It Among the Best NASDAQ Penny Stocks to Invest In Now?1
15.07.Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 20242
21.06.Organogenesis Holdings Inc. - 8-K, Current Report1
06.06.Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference2
03.04.Organogenesis Holdings Inc.: Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case168CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization...
► Artikel lesen
29.02.Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance218CANTON, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1